This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: EAS Academy

Themed Short Track:

Wednesday 20 February 2019   (0 Comments)
Share |

Introducing Themed Short Tracks

In SHORT TRACKS we collect 2-4 recent lectures from EAS congresses or courses, putting them together to provide up-to-date perspectives on a given current topic.

This month’s SHORT TRACK  selection focuses on risk stratification and novel insights into lipid and other biomarkers of (not only) CVD.

There are many new risk markers and biological variables associated with CVD risk emerging rapidly in different types of experimental as well as clinical studies. But do they really contribute to better stratification of CVD risk? What is their practical added value over the established risk stratification tools ? And what parameters do we need to take into account when assessing the utility of different new biomarkers in practice? These are only a few questions that are going to be addressed in the selected SHORT TRACT presentation from the EAS Academy we are bringing you in March

To the SHORT TRACK selection focuses on risk stratification and novel insights into lipid and other biomarkers of (not only) CVD>>

These presentations are open for EAS members only. Register as an EAS Individual member, and the whole ACADEMY is open for you.

How to register as an EAS member >>

Do Novel Biomarkers improve cardiovascular risk stratification?

Arnold von Eckardstein, Professor at the Medical Faculty of the University of Zurich and Director of the Institute of Clinical Chemistry of the University Hospital of Zurich, Switzerland.

Despite all the progress of our understanding of processes underlying atherosclerotic vascular disease our ability to predict events based on risk stratification still seems suboptimal. Thus, the search for novel markers improving our predictive power continues. However, identification of new ones requires rigorous approaches to prove causality and additive value over the currently used risk stratification tools. Professor Arnold von Eckardstein clearly explains what the requirements to prove causality are and gives nice examples from the lipid field.

                                                                                                           To the presentation>>

Causality of lipid traits for other diseases

Ruth Frikke-Scmidt, MD, PhD, DMSc is Chief Physician at the Department of Clinical Biochemistry, Rigshospitalet, and Associate Research Professor at the Department of Clinical Medicine, University of Copenhagen, Denmark.

In her excellent and up-to-date overview, dr. Ruth Frikke-Schmidt summarizes important novel data regarding the role of lipids and lipoproteins in the development of non-cardiovascular disease. After viewing the lecture, you will be able to answer some of the burning questions e.g. relationships between lipids and the risk of cognitive impairment or the mechanism underlying the increased risk of new                                   onset diabetes seen with statins.

                                                                                                           To the presentation>>

Membership Software Powered by YourMembership  ::  Legal